N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide structure
|
Common Name | N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide | ||
|---|---|---|---|---|
| CAS Number | 1246203-32-6 | Molecular Weight | 588.629 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 769.9±70.0 °C at 760 mmHg | |
| Molecular Formula | C26H30F2N8O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 419.4±35.7 °C | |
| Name | N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide |
|---|---|
| Synonym | More Synonyms |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 769.9±70.0 °C at 760 mmHg |
| Molecular Formula | C26H30F2N8O4S |
| Molecular Weight | 588.629 |
| Flash Point | 419.4±35.7 °C |
| Exact Mass | 588.207886 |
| PSA | 135.98000 |
| LogP | 2.44 |
| Vapour Pressure | 0.0±2.6 mmHg at 25°C |
| Index of Refraction | 1.664 |
| InChIKey | GDCJHDUWWAKBIW-UHFFFAOYSA-N |
| SMILES | COc1cccc2c1nc(C(F)F)n2-c1nc(-c2ccc(NS(=O)(=O)CCN(C)C)cc2)nc(N2CCOCC2)n1 |
|
~%
N-[4-[4-[2-(dif... CAS#:1246203-32-6 |
| Literature: Pathway Therapeutics Limited Patent: US2010/249099 A1, 2010 ; Location in patent: Page/Page column 83 ; US 20100249099 A1 |
| Precursor 2 | |
|---|---|
| DownStream 1 | |
| Ethanesulfonamide, N-[4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)- |
| N-{4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}-2-(dimethylamino)ethanesulfonamide |
| N-(4-{4-[2-(Difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl}phenyl)-2-(dimethylamino)ethanesulfonamide |
| N-(4-(4-(2-(difluoromethyl)-4-methoxy-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-2-(dimethylamino)ethanesulfonamide |